Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-02-06

Clinical Trial Update: Rituximab + Immunotherapy in Follicular Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial of Rituximab plus immunotherapy in follicular lymphoma was terminated. Results were posted on 2025-02-06.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Rituximab (rituximab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Follicular Lymphoma | Phase 1 | Status: TERMINATED | Results posted: 2025-02-06